Search clinical trials for: telmisartan + HCTZ

Total 532 results

Boehringer Ingelheim

Completed

Relative Bioavailability of Telmisartan and HCTZ in Two Experimental Formulations Compared to the Standard Formulation Telmisartan and HCTZ in Healthy Female and Male Subjects

Healthy
Boehringer Ingelheim

Completed

Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension

Hypertension

Japan
Boehringer Ingelheim

Completed

Pharmacokinetics of Different Formulations of Telmisartan, Amlodipine, and Hydrochlorothiazide (HCTZ) in Japanese Healthy Male Volunteers

Healthy

Japan
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan/ HCTZ Fixed Dose Combination Compared With Its Monocomponents in Healthy Male Volunteers II

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan as Telmisartan 80 mg/HCTZ 12.5 mg Fixed-dose Combination Tablet or as Two Telmisartan 40 mg Tablets in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Failed in Telmisartan 80 mg

Hypertension

China
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising and Multiple Oral Doses of Telmisartan / Hydrochlorothiazide (HCTZ) in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan Monotherapy

Hypertension

Japan
Boehringer Ingelheim

Completed

Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential Hypertension

Hypertension

China
Boehringer Ingelheim

Completed

Telmisartan80/HCTZ25 Versus Telmisartan80/HCTZ12.5 in Hypertension Not Responding to Telmisartan80/HCTZ12.5

Hypertension

France, Switzerland, Italy, Germany, Hong Kong, Netherlands, South Africa, Spain, Taiwan, Denmark, Sweden, Finland, Ireland, Korea, Republic of, Malaysia, Norway
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan / HCTZ Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan / HCTZ of Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

An Observational Study to Investigate the Efficacy, Safety, Tolerability and the Effect on Quality of Life of Telmisartan (Micardis) and Telmisartan With HCTZ (Micardis Plus) in Patients With Hypertension

Hypertension

Korea, Republic of
Boehringer Ingelheim

Completed

Telmisartan Tab Hypertension

Hypertension
Boehringer Ingelheim

Completed

Influence of Food on the Bioavailability of Two Doses of Telmisartan/HCTZ Fixed-dose Combination in Japanese Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Relative Oral Bioavailability of Telmisartan / Hydrochlorothiazide (HCTZ) Fixed Dose Combination (FDC) Compared With Its Monocomponents in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Telmisartan/Hydrochlorothiazide (HCTZ) Fixed Dose Combination Compared to Its Monocomponents in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination

Hypertension

Japan
Boehringer Ingelheim

Completed

Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine

Hypertension

Japan
Emory University
National Institute on Aging (NIA)

Completed

Health Evaluation in African Americans Using RAS Therapy (HEART)

Alzheimer's Disease

United States
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan Film-coated Tablet Compared With the Conventional Telmisartan Tablet Following Oral Administration in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Evaluation of the Effect of Telmisartan on Blood Pressure Control of High Risk Patients

Hypertension

Romania
Vanderbilt University Medical Center

Completed

The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function

High Blood Pressure

United States
Boehringer Ingelheim

Completed

Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension (MicCAT)

Hypertension
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan Film-coated Tablet Compared With Two Tablets of the Conventional Telmisartan Tablet in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Natriuretic Effect of Telmisartan Versus Placebo in Patients With Mild-to-Moderate Hypertension

Hypertension
University of Missouri-Columbia

Completed

Optimal HCTZ Cessation for Diagnosis of Hyperparathyroidism

Hyperparathyroidism

United States
Boehringer Ingelheim

Completed

INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic Nephropathy

Diabetic Nephropathies

Japan
IlDong Pharmaceutical Co Ltd

Completed

Compare the Pharmacokinetics of TAH(80/10/12.5) Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

Efficacy and Safety of Telmisartan in Hypertensive Patients With Mild/Moderate or Severe Renal Impairment or Requiring Hemodialysis (ESPRIT)

Hypertension
Laboratorio Elea Phoenix S.A.
Carlos R. Rojo, MD; Facultad de Medicina, Universidad de Buenos Aires, UBA

Completed

Telmisartan for Treatment of COVID-19 Patients

COVID-19 Drug Treatment

Argentina
Boehringer Ingelheim

Withdrawn

Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice

Hypertension

Japan
Novartis

Completed

A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients

Hypertension

United States, Germany
Novartis

Completed

Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension

Hypertension

United States, Germany
Novartis

Completed

A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients. (ANDROMEDA)

High Blood Pressure

Venezuela
Boehringer Ingelheim

Completed

Telmisartan in Mild to Moderate Hypertensive Patients

Hypertension
Yuhan Corporation

Completed

Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment

Hypertension

Korea, Republic of
Boehringer Ingelheim

Completed

Micardis®. Observational Study in Patients With Essential Hypertension

Hypertension
Boryung Pharmaceutical Co., Ltd
Chonbuk National University Hospital; Samsung Medical Center; Asan Medical Center and other collaborators

Completed

A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy

Essential Hypertension

Korea, Republic of
Boehringer Ingelheim

Completed

Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension

Hypertension

United States, Bulgaria, Czech Republic, France, Hungary, Korea, Republic of, Romania, Russian Federation, Slovakia, Spain, Ukraine
VA Office of Research and Development

Completed

Diuretic Comparison Project (DCP)

Hypertension

United States, Puerto Rico
University of South Carolina
Duke University; Kilimanjaro Christian Medical Centre, Tanzania

Completed

Does Preference-based HIV Testing Increase Uptake in High Risk Populations? (DCE-IMPACT)

HIV Testing

United States, Tanzania
Boehringer Ingelheim

Terminated

SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients

Hypertension | Coronary Arteriosclerosis

Germany
Ludwig-Maximilians - University of Munich
Bayer

Completed

Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients (METATEL)

Hypertension | Metabolic Syndrome | Hypertriglyceridemia

Germany
The First Affiliated Hospital of Soochow University
First Affiliated Hospital Xi'an Jiaotong University; Ruijin Hospital; Wuhan Union... and other collaborators

Recruiting

Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients

Haploidentical Hematopoietic Stem Cell Transplantation | Cord Blood | Acute T Cell Lymphoblastic Leukemia

China
The First Affiliated Hospital of Soochow University
Zhejiang University; The Second People's Hospital of Huai'an; Soochow Hopes Hematology... and other collaborators

Completed

Haplo HCT vs Haplo-cord HCT for Patients With AML

Acute Myeloid Leukemia | Hematopoietic Stem Cell Transplantation | Haplo-identical Donor | Cord Blood Unit

China
Boehringer Ingelheim

Completed

Filtered Trial for Telmisartan 40mg Non-responder

Hypertension

Japan
Boehringer Ingelheim

Completed

Study of Hypertensive Population Under Treatment With Telmisartan in Real Clinical Conditions With the Goal to Control Early Morning Blood Pressure Rise

Hypertension

Belgium, Canada, Colombia, Czechia, Ecuador, Indonesia, Jordan, Lebanon, Mexico, Turkey, Venezuela, Yemen
University of Campania "Luigi Vanvitelli"

Completed

Telmisartan in Haemodialysis Patients With Chronic Heart Failure

Heart Failure, Congestive

Italy
Boehringer Ingelheim

Completed

Micardis® in Patients With Essential Hypertension

Hypertension

3

Subscribe